If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
Results of the Phase III TROPIC global study published BRIDGEWATER, N.J., Oct. 1 (HSMN NewsFeed) — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food…
Biopharmaceuticals, Oncology
sanofi-aventis, TROPIC study, Jevtana, cabazitaxel, prostate cancer
Posts from ‘September, 2010’
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Elekta Launches ABAS 2.0 Autosegmentation Software Used to Plan Radiation Therapy in Patients With Cancer
GPU calculations increase contouring speed by as much as 50 percent ATLANTA, Oct. 1 (HSMN NewsFeed) — Elekta recently launched ABAS (Atlas-based Autosegmentation) TWO.0 software, which includes the Simultaneous Truth and Performance Level Estimation (S…
Devices, Oncology
Elekta, Atlas-based Autosegmentation, radiotherapy, treatment plan
Minnow Pharma Names Raymond W. Cohen as Chief Executive Officer
Pharma Device Veteran Has More Than Twenty five Years of Leadership, Entrepreneurial Experience in Health Care LAGUNA HILLS, Calif., Sept. 30 (HSMN NewsFeed) — Minnow Clinical, Inc., a developer of a novel platform technology employing radiofrequency thermopl…
Devices, Interventional, Personnel
Minnow Medical, in-stent restenosis
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
NOVATO, Calif., Sept. 23 (HSMN NewsFeed) — BioMarin Medical Inc. (Nasdaq:BMRN ) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. "We are extremely pleased to welcome William Young and Kenn…
Biopharmaceuticals, Personnel
BioMarin Medical, Naglazyme, Aldurazyme
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
SOUTH SAN FRANCISCO, CA–(Healthcare Sales & Product management Network) - Portola Pharmaceuticals, Inc. today announced the appointment of Jean-Jacques Bienaimé to the company’s board of directors. Mr. Bienaimé currently serves as chief executive off…
Biopharmaceuticals, Personnel
Portola Pharmaceuticals
Angel Clinical laboratory Systems Receives CE Mark Approval for the AngelMed Guardian, an Implantable Device Designed to Provide Early Warning of a Heart Attack
SHREWSBURY, N.J., Sept. 22 (HSMN NewsFeed) — Angel Medical Systems announced today that it has received CE (Conformite Europeenne) Mark approval for the commercial sale of The AngelMed Guardian System in Europe. The Guardian System is an implantable ea…
Devices, Cardiology, Regulatory
Angel Pharma Systems, AngelMed Guardian System
Abbott’s Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
Positive Data at Six and Nine Months Affirm Groundbreaking Potential of Abbott’s Bioresorbable Vascular Scaffold as a Promising Alternative to Coronary Stenting ABBOTT PARK, Ill., Sept. 22 (HSMN NewsFeed) — Abbott (NYSE:ABT ) today announced positive…
Devices, Interventional Cardiology
Abbott, ABSORB trial, bioresorbable vascular scaffold
Boston Scientific’s TAXUS(R) Element Stent Demonstrates Strong Outcomes in Diabetic Patients
Company presents one-year clinical data at TCT on its platinum chromium paclitaxel-eluting coronary stent from PERSEUS trial NATICK, Mass., Sept. 22 (HSMN NewsFeed) — Boston Scientific Corporation (NYSE:BSX ) today announced results from an analysis…
Devices, Interventional Cardiology
Boston Scientific, TAXUS Element, Paclitaxel, drug eluting stent
Long-Term Data Show Advantages for TAXUS(R) Liberte(R) Stent in Diminutive Vessels and Long Lesions
Results of TAXUS ATLAS medical program presented at TCT NATICK, Mass., Sept. 22 (HSMN NewsFeed) — Boston Scientific Corporation (NYSE:BSX ) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, si…
Devices, Interventional Cardiology
Boston Scientific, TAXUS, Liberte, Paclitaxel, drug eluting stent
Vycor Medical Continues to Build Its Sales and Marketing Infrastructure for Its ViewSite(TM) Neurosurgery Retraction Devices
Vycor Pharmaceutical Appoints a National Revenue Director and New Distributors for Its ViewSite Brain Access Systems in the US and Internationally — Now Part of the Company’s Global Distribution Network That Encompasses the US, Canada, the Benelux, Spain, Italy, G…
Devices, Neurosurgery, Personnel
Vycor Pharmaceutical, ViewSite, Surgical Access System, retractor
